BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines rEVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL)
Latest, Q4 2024
3.60
Period ended Dec 31, 2024
Change on a year earlier
-77.6%
16.1 in Q4 2023
History
24 quarters
Since Q1 2019
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 3.60 | -77.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 11.1 | -26.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 9.10 | -58.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 12.2 | -47.4% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 16.1 | -12.5% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 15 | -21.5% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 21.9 | +10.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 23.2 | +6.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 18.4 | -20.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 19.1 | -5.4% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 19.9 | +95.1% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 21.7 | +30.7% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 23.1 | +171.8% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 20.2 | +43.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 10.2 | -40.7% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 16.6 | +118.4% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 8.50 | -55.5% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 14.1 | -25.8% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 17.2 | +4.9% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 7.60 | -67.8% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 19.1 | – | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 19 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 16.4 | – | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 23.6 | – | Form 10-Q (filed 2020-05-11) ↗ |
Cite this data
StockData. (2026). BeOne Medicines REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M), quarterly Q1 2019–Q4 2024 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_revlimid
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.